Aerovate Therapeutics Files 8-K Report

Ticker: JBIO · Form: 8-K · Filed: Mar 27, 2024 · CIK: 1798749

Sentiment: neutral

Topics: 8-K, financial-statements, exhibits

TL;DR

AeroVate filed a routine 8-K, mostly financial docs. Nothing major to see here.

AI Summary

On March 27, 2024, Aerovate Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating routine corporate disclosures rather than a specific material event. No significant financial figures or new strategic developments were detailed in the provided excerpt.

Why It Matters

This filing indicates Aerovate Therapeutics is providing standard corporate disclosures to the SEC, which is a routine part of maintaining public company status.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for financial statements and exhibits, not indicating any immediate material changes or risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by Aerovate Therapeutics, Inc.?

The primary purpose of this 8-K filing is to report financial statements and exhibits, as indicated by the 'ITEM INFORMATION: Financial Statements and Exhibits' section.

When was this 8-K report filed?

This 8-K report was filed on March 27, 2024.

What is Aerovate Therapeutics, Inc.'s principal executive office address?

Aerovate Therapeutics, Inc.'s principal executive offices are located at 930 Winter Street, Suite M-500, Waltham, Massachusetts 02451.

What is Aerovate Therapeutics, Inc.'s IRS Employer Identification Number?

Aerovate Therapeutics, Inc.'s IRS Employer Identification Number is 83-1377888.

Under which section of the Securities Exchange Act of 1934 is this report filed?

This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Filing Stats: 533 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-03-27 09:22:32

Key Financial Figures

Filing Documents

01

Item 7.01 Regulation FD Disclosure. Aerovate Therapeutics, Inc. (the "Company") is furnishing a corporate presentation, attached as Exhibit 99.1 to this Current Report on Form 8-K, which the Company intends to use from time to time in meetings with investors and others beginning on March 27, 2024. The corporate presentation will also be available in the "Events & Presentations" section of the Company's website at https://ir.AerovateTx.com/events-presentations. The information under this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits HIDDEN_ROW 99.1 Corporate presentation of Aerovate Therapeutics, Inc., furnished herewith. 104 Cover Page Interactive Data File SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aerovate Therapeutics, Inc. Date: March 27, 2024 By: /s/ George A. Eldridge George A. Eldridge Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing